

Ready for leverage

Total Brain (ASX:TTB) is the developer of a neuroscience-based mental health & fitness platform powered by the largest standardized neuroscientific database in the world formed over almost two decades and with \$50m of R&D funding. Total Brain has reported an 8.7% decline in H1FY20 revenue over H1FY19 to \$2.02m, chiefly due to a decline in one-off revenues associated with its data licencing. The net loss for the period was \$4.06m, slightly ahead of pcp and in line with our expectations. Costs for the half rose only 1.3% and were better than our expectations with a 13.5% reduction in non-human capital costs. Total Brain continued to invest in people with employment costs rising 8.7% in the half. We have made minor adjustments to our FY21 forecasts as a result. Importantly, the result demonstrated the focus shift to SaaS revenues and a cost base ready for leverage from new revenue streams from Affinity partners, in particular the IBM Mental Fitness platform which is just waiting government agency sign-off.

Business model

Total Brain operates a subscription as a service (SaaS) model for its mental health and fitness platform. The science behind the platform has been developed over almost two decades with input from the leading academic institutions in the field. This has generated a proprietary neuroscientific database of scale which underpins the scientific validation that differentiates Total Brain from other brain training and wellness applications. The app, promoted by affinity partners, assesses the four core brain capacities (emotion, feeling, cognition, self-control), pre-screens seven common mental health conditions and delivers personalised brain and mind/body training.

H1FY20 result and earnings adjustments

Total Brain announced H1FY20 revenues of \$2.0m, an 8.6% decline on the previous corresponding period (pcp) and reflecting the company's deliberate shift away from one-off revenue. The decrease was driven by a \$0.7m decline relating to licencing of the i-SPOT scientific data which was recorded in the pcp. Offsetting this was a \$0.6m increase in recurring SaaS revenues in the corporate and affinity markets. Management expects growth in this core business to accelerate over the coming quarters, reflecting the year on year 28% increase in Annual Recurring Revenue to \$3.5m. Revenue for the half was below our forecasts, largely due to timing differences in corporate revenues coming on board. Costs were very well contained in the half year, rising just 1.3% despite a significant additional investment (\$0.32m) in personnel in the half year. The cost containment was significantly better than our forecast, resulting the net loss for the half (\$4.0m) being in line with our expectations. We have trimmed our FY21 revenues but also reduced cost expectations, resulting in no meaningful change to our FY21 forecast.

Base case valuation is \$136.8m or \$1.26/share

We use the discounted cashflow methodology to value Total Brain, arriving at a base case valuation of \$136.8m which derives a per share valuation of \$1.26. The terminal value in our base case valuation is \$0.69/share. At the current share price, Total Brain is trading at a significant discount to a group of Australian SaaS peers focused on advancing solutions for human well-being. We see the advancement of the IBM Mental Fitness 360 programme to US veterans as the key near term catalyst for Total Brain's share price.

Historical earnings and RaaS Advisory estimates

Year end	Revenue (A\$m)	Gross Profit (A\$m)	EBITDA reported (A\$m)	NPAT reported (A\$m)	EPS* (c)	EV/Sales (x)
06/19a	2.6	2.3	(6.7)	(8.6)	(12.21)	5.0
06/20a	3.9	3.2	(7.4)	(7.6)	(8.07)	5.0
06/21e	5.9	5.1	(6.9)	(7.3)	(6.73)	5.5
06/22e	14.1	12.0	(1.8)	(2.3)	(2.15)	2.6

Source: Company data, RaaS estimates for FY21e, FY22e *adj for one-time items

Healthcare services

26th February 2021

Share details

ASX Code	TTB
Share price (25 Feb)	\$0.32
Market Capitalisation	\$34.7M
Shares on issue	108.3M
Net cash at 31 Dec '20	\$2.7m
Free float	~57%

Share performance (12 months)



Upside Case

- Highly scalable SaaS model
- Significant validation achieved with IBM choosing the platform as the engine for Mental Fitness 360
- Targeting predominantly US corporates and consumers

Downside Case

- Enterprise sales cycle for the B2B product takes from 9-18 months
- New consumer product yet to be fully trialed in market
- Commercial success to date has been elusive

Board of Directors

Dr Evian Gordon	Executive Chairman/ Founder
Louis Gagnon	Managing Director/ CEO
Matthew Morgan	Non-Executive Director
David Torrible	Non-Executive Director
David Daglio	Non-Executive Director

Company contact

Emil Vasilev (CFO) +646 763 3264
emil@totalbrain.com

RaaS Advisory contact

Finola Burke* +61 414 354 712
finola.burke@raasgroup.com

*The analyst holds shares

H1FY21 result

Total Brain reported an 8.7% reduction in revenue in H1FY21 over H1FY20 but a 3.2% increase in Gross Profit to \$1.86m. Costs increased just 1.3% in the half, despite an 8.7% lift in employee costs. We had anticipated higher employment costs in the half but also higher revenues from corporate clients. Bottom line, the result was in line with our expectations. We set out in the following exhibit the H1FY21 result versus the previous corresponding period and our forecast.

Exhibit 1: H1FY20 vs H1FY19 and RaaS estimates				
	H1FY20 Actual	H1FY21 Actual	% Chg	RaaS H1FY2 forecast
Revenue	2.19	2.00	(8.7%)	2.38
Gross profit	1.80	1.86	3.2%	2.02
GP%	82.3%	93.0%	13.0%	84.7%
Employment	3.70	4.02	8.7%	4.27
SGA&A	1.87	1.62	(13.5%)	1.63
EBITDA underlying	(3.80)	(4.06)	7.0%	(3.88)
EBIT underlying	(3.93)	(4.11)	4.5%	(4.08)
NPAT	(3.92)	(4.06)	3.5%	(4.02)
EPS	(4.76)	(3.75)	(21.3%)	(3.71)

Source: Company data, RaaS estimates

A key feature of the result was the lift in revenues from Total Brain's Affinity partnerships which are becoming a growing contributor to overall revenues. While Corporate clients delivered a lower than forecast result, the growth from B2B was still up more than 18%.

Exhibit 2: Revenue breakdown			
	H1FY20 Actual	H1FY21cActual	RaaS H1FY21 Forecast
Total Brain Corporate	1.08	1.28	1.56
Total Brain Affinity	0.08	0.55	0.60
Total Brain all other	0.10	0.01	0.04
Clinical	0.18	0.14	0.15
Discovery	0.02	0.01	0.01
Data Licencing	0.73	-	0.01
Revenue	2.19	2.00	2.38

Source: Company data, RaaS estimates

Total Brain ended H1FY21 with net cash of \$2.7m and noted that based on closing cash balance at December 31, receipts collected in January 2021 (including a \$1.1m R&D tax incentive from the Australian government) and additional cash collections scheduled over the next three months, the cash runway for the business runs to June 2021. This excludes any billings from the pending IMB transaction or other net new contract wins. The company is also potentially eligible for \$1.4m in stimulus funding from the US government through the second round of the Paycheck Protection Program which would extend the runway of the business to August 2021.

Earnings adjustments

We have adjusted our forecasts to reflect lower than forecast B2B revenues. This has flowed through to modest adjustments with a small pullback in the net loss we are forecasting for FY21. Our forecasts beyond FY21 are unchanged. We set out our changes in the following exhibit.

Exhibit 3: Earnings adjustments			
	FY21 old	FY21 new	% chg
Revenue	6.2	5.9	(6.1%)
Gross profit	5.3	5.1	(3.0%)
EBITDA underlying	(6.9)	(6.9)	0.6%
EBIT underlying	(7.3)	(7.3)	0.3%
NPBT	(7.3)	(7.3)	1.1%
NPAT	(7.3)	(7.3)	0.2%

Source: RaaS estimates

DCF valuation

We are of the view that the discounted cashflow methodology is the most appropriate methodology for valuing early stage companies. Our base case DCF valuation of Total Brain is \$136.8m which derives a \$1.26/share valuation. Our terminal value is \$0.69/share within this valuation.

Exhibit 4: Base Case DCF valuation	
Parameters	Outcome
Discount Rate / WACC	14.7%
Beta	2.0
Terminal growth rate assumption	2.20%
Sum of PV	61.2
PV of terminal Value	72.8
PV of Enterprise	134.0
Debt (Cash)	(2.7)
Net Value - Shareholder	136.8
No of shares on issue (m)	108.3
NPV	\$1.26
Source: RaaS estimates	

Peer comparison

We have considered a group of ASX-listed SaaS peers with an emphasis on advancing solutions for human well-being. US domiciled and focused Limeade Inc (ASX:LME) has a platform focused on employee well-being, engagement, inclusion, social recognition and communication services while Life360 Inc (ASX:360), also US-based, has created a location-monitoring platform focused on family well-being and protection. Both Limeade and Life360 are still loss making. Damstra Holdings (ASX:DTC) has developed a platform for workforce management solutions, including employee safety solutions acquired in the takeover of Vault Intelligence. Damstra is profitable, reporting EBITDA of \$1.2m in FY20 and forecasted by consensus to report \$6.87m EBITDA in FY21 (which puts it on a forward EV/EBITDA multiple of 36x).

The median last reported EV/revenue multiple of these peers is 8.9x while on a forward EV/Revenue basis the median is 6.4x. In comparison, Total Brain is trading on an EV/Revenue multiple of 5.5x based on its FY20 revenues and 5.0x our forecast for FY21., putting it at a substantial discount to these peers.

Exhibit 5: Peer comparison					
Company Name	Code	Market cap (A\$m)	Enterprise value (A\$m)	EV/Revenue last reported (x)	EV/Revenue fwd (x)
Limeade Inc	LME	375	343	7.2	6.1
Life360 Inc	360	589	525	8.9	6.4
Damstra Holdings	DTC	249	244	12.5	7.7
Median		375	343	8.9	6.4
Source: Refinitiv Eikon, RaaS analysis Prices at 25 February 2021					

Exhibit 6: Financial year financial summary (In A\$m)

Total Brain (TTB.AX)						Share price (25 February 2021)						A\$	0.31
Profit and Loss (A\$m)						Interim (A\$m)	H119A	H219A	H120A	H220A	H121F	H221F	
Y/E 30 June	FY18A	FY19A	FY20A	FY21F	FY22F	Revenue	1.1	1.5	2.2	1.7	2.0	3.9	
Revenue	2.6	2.6	3.9	5.9	14.1	EBITDA	(4.4)	(3.7)	(3.8)	(3.6)	(3.9)	(3.0)	
Gross profit	2.5	2.3	3.2	5.1	12.0	EBIT	(4.5)	(4.0)	(3.9)	(3.7)	(4.1)	(3.2)	
GP margin %	95.3%	87.8%	83.4%	87.6%	84.7%	NPAT (normalised)	(4.5)	(4.1)	(3.9)	(3.7)	(4.1)	(3.2)	
EBITDA	(4.9)	(6.7)	(7.4)	(6.9)	(1.8)	Minorities	0.0	0.0	0.0	0.0	0.0	0.0	
Depn	(0.0)	(0.0)	(0.1)	(0.1)	(0.0)	NPAT (reported)	(4.5)	(4.1)	(3.9)	(3.7)	(4.1)	(3.2)	
Amort	(0.1)	(0.4)	(0.2)	(0.4)	(0.5)	EPS (normalised)	(6.9)	(0.6)	(4.8)	(3.3)	(3.7)	(3.0)	
EBIT	(23.4)	(7.2)	(7.7)	(7.3)	(2.3)	EPS (reported)	(6.9)	(0.6)	(4.8)	(3.3)	(3.7)	(3.0)	
Interest	(0.5)	0.0	0.0	(0.0)	(0.1)	Dividend (cps)	0.0	0.0	0.0	0.0	0.0	0.0	
Tax	0.8	0.0	0.0	0.1	0.0	Imputation	30.0	30.0	30.0	30.0	30.0	30.0	
Minorities	0.0	0.0	0.0	0.0	0.0	Operating cash flow	(2.3)	(3.4)	(4.3)	(1.7)	(4.3)	(0.5)	
Equity accounted assoc	(0.0)	0.0	0.0	0.0	0.0	Free Cash flow	(1.0)	(2.0)	(3.2)	(0.1)	(1.8)	0.6	
NPAT pre significant items	(23.1)	(8.6)	(7.6)	(7.3)	(2.3)	Divisionals	H119A	H219A	H120A	H220A	H121F	H221F	
Significant items	0.0	0.0	0.0	0.0	0.0	Total Brain - Corporate	0.9	0.9	1.1	1.2	1.3	2.0	
NPAT (reported)	(23.1)	(8.6)	(7.6)	(7.3)	(2.3)	Total Brain Affinity	-	0.2	0.1	0.3	0.6	1.6	
Cash flow (A\$m)						Other revenues	0.2	0.4	1.0	0.2	0.2	0.3	
Y/E 30 June	FY18A	FY19A	FY20A	FY21F	FY22F	Total Revenue	1.1	1.5	2.2	1.7	2.0	3.9	
EBITDA	(4.9)	(6.7)	(7.4)	(6.9)	(1.8)								
Interest	0.0	0.0	0.0	(0.0)	(0.1)	Gross profit	1.0	1.3	1.8	1.4	1.9	3.3	
Tax	0.0	0.0	0.0	0.0	0.0	Gross Profit Margin %	89%	87%	82%	85%	93%	85%	
Working capital changes	1.0	1.1	1.4	2.1	(0.0)	Employment	2.8	2.7	3.7	3.1	4.0	4.4	
Operating cash flow	(3.9)	(5.6)	(6.0)	(4.8)	(1.8)	Marketing	0.4	0.4	0.4	0.5	0.4	0.5	
Mtce capex	0.0	0.0	(0.1)	(0.1)	(0.1)	Other costs	1.2	1.3	1.5	1.2	1.2	1.3	
Free cash flow	(3.9)	(5.6)	(6.1)	(4.9)	(1.9)	Total costs	4.4	4.4	5.6	4.8	5.6	6.3	
Growth capex	(1.7)	(2.7)	(2.6)	(3.5)	(2.0)	EBITDA	(3.4)	(3.1)	(3.8)	(3.4)	(3.8)	(3.0)	
Acquisitions/Disposals	0.0	0.0	0.0	0.0	0.0								
Other	(0.1)	0.1	0.0	0.0	0.0								
Cash flow pre financing	(5.7)	(8.2)	(8.7)	(8.4)	(3.9)								
Equity	10.5	6.7	13.7	0.0	0.0	Margins, Leverage, Returns	FY18A	FY19A	FY20A	FY21F	FY22F		
Debt	(0.1)	0.0	1.1	0.0	0.0	EBITDA margin %		(186.7%)	(258.7%)	(191.6%)	(117.9%)	(12.5%)	
Dividends paid	0.0	0.0	0.0	0.0	0.0	EBIT margin %		(893.4%)	(274.8%)	(197.6%)	(125.1%)	(16.0%)	
Net cash flow for year	4.7	(1.5)	6.0	(8.4)	(3.9)	NPAT margin (pre significant items)		(882.9%)	(329.4%)	(197.2%)	(124.1%)	(16.5%)	
Balance sheet (A\$m)						Net Debt (Cash)		6.62	5.21	10.00	1.18	-	2.76
Y/E 30 June	FY18A	FY19A	FY20A	FY21F	FY22F	Net debt/EBITDA (x)	(x)	n/a	n/a	n/a	n/a	n/a	
Cash	6.6	5.2	11.1	2.2	(1.8)	ND/ND+Equity (%)	(%)	(43.6%)	(34.8%)	(61.0%)	(6.8%)	14.4%	
Accounts receivable	1.3	0.8	2.8	0.9	1.2	EBIT interest cover (x)	(x)	n/a	n/a	n/a	n/a	n/a	
Inventory	0.0	0.0	0.0	0.0	0.0	ROA		(95.8%)	(32.3%)	(30.2%)	(28.6%)	(10.8%)	
Other current assets	0.0	0.2	0.1	0.4	0.4	ROE		(124.4%)	(40.8%)	(32.8%)	(32.3%)	(13.3%)	
Total current assets	8.0	6.2	14.1	3.4	(0.2)	ROIC		(162.5%)	(109.5%)	(159.0%)	(108.2%)	(47.3%)	
PPE	0.2	0.2	0.3	0.3	0.4	NTA (per share)		41.0%	34.4%	27.8%	17.3%	15.1%	
Goodwill	0.0	0.0	0.0	0.0	0.0	Working capital		82.8%	35.3%	237.6%	63.1%	94.1%	
Intangibles	14.7	14.9	15.0	18.2	19.7	WC/Sales (%)		31.6%	13.6%	61.3%	10.7%	6.7%	
Deferred tax asset	0.0	0.0	0.0	0.0	0.0	Revenue growth		10.4%	(0.5%)	49.0%	51.3%	140.7%	
Other non current assets	0.0	0.0	0.0	0.0	0.0	EBIT growth pa		n/a	n/a	n/a	n/a	n/a	
Total non current assets	14.9	15.2	15.3	18.5	20.1	Pricing	FY18A	FY19A	FY20A	FY21F	FY22F		
Total Assets	22.9	21.4	29.4	21.9	19.9	No of shares (y/e)	(m)	53	59	95	108	108	
Accounts payable	0.5	0.5	0.5	0.2	0.2	Weighted Av Dil Shares	(m)	36	59	95	108	108	
Short term debt	0.0	0.0	1.1	1.0	1.0								
Tax payable	0.0	0.0	0.0	0.0	0.0	EPS Reported	cps	(6.38)	(14.58)	(8.07)	(6.73)	(2.15)	
Deferred revenue	0.5	0.6	1.4	2.0	2.3	EPS Normalised/Diluted	cps	(12.98)	(12.21)	(8.07)	(6.73)	(2.15)	
Total current liabilities	1.0	1.1	3.0	3.2	3.5	EPS growth (norm/dil)		n/a	n/a	n/a	n/a	nm	
Long term debt	0.0	0.0	0.0	0.0	0.0	DPS	cps	-	-	-	-	-	
Other non current liabs	0.1	0.1	0.1	0.0	0.1	DPS Growth		n/a	n/a	n/a	n/a	n/a	
Total long term liabilities	0.1	0.1	0.1	0.0	0.1	Dividend yield		0.0%	0.0%	0.0%	0.0%	0.0%	
Total Liabilities	1.1	1.2	3.0	3.2	3.6	Dividend imputation		30	30	30	30	30	
Net Assets	21.8	20.2	26.4	18.7	16.4	PE (x)		-	-	-	-	-	
						PE market		18	18	18	18	18	
Share capital	58.1	64.8	78.4	78.4	78.4	Premium/(discount)			(100.0%)	(100.0%)	(100.0%)	(100.0%)	
Accumulated profits/losses	(40.2)	(48.8)	(56.4)	(63.7)	(66.0)	EV/EBITDA		(4.7)	(1.9)	(2.6)	(4.7)	-	20.6
Reserves	3.9	4.2	4.4	4.0	4.0	FCF/Share	cps	(7.3)	(9.6)	(6.2)	(4.3)	-1.6	
Minorities	0.0	0.0	0.0	0.0	0.0	Price/FCF share		(4.2)	(3.2)	(5.0)	(7.1)	-	19.2
Total Shareholder funds	21.8	20.2	26.4	18.7	16.4	Free Cash flow Yield		(23.6%)	(31.0%)	(20.0%)	(14.0%)	(5.2%)	

Source: RaaS Advisory

Exhibit 7: Calendar year financial summary (in A\$m)

Total Brain (ASX:TTB)						Share price (25 February 2021)						A\$		0.31
Profit and Loss (A\$m)						Interim (A\$m)		H1CY18A	H2CY18A	H1CY19F	H2CY19A	H1CY20A	H2CY20F	
Y/E December 31	CY18A	CY19A	CY20F	CY21F	CY22F	Revenue	1.6	1.1	1.5	2.2	1.7	2.0		
Revenue	2.7	3.7	3.7	9.9	19.4	EBITDA	(5.9)	(4.4)	(3.7)	(3.8)	(3.6)	(3.9)		
Gross profit	2.5	3.1	3.3	8.4	16.3	EBIT	(9.3)	(4.5)	(4.0)	(3.9)	(3.7)	(4.1)		
GP margin %	93.5%	84.2%	89.2%	84.7%	84.2%	NPAT (normalised)	(11.0)	(4.5)	(4.1)	(3.9)	(3.7)	(4.1)		
EBITDA	(10.2)	(7.5)	(7.6)	(4.6)	1.8	Minorities	0.0	0.0	0.0	0.0	0.0	0.0		
Depn	(0.0)	(0.1)	(0.1)	(0.0)	(0.0)	NPAT (reported)	(11.0)	(4.5)	(4.1)	(3.9)	(3.7)	(4.1)		
Amort	(0.2)	(0.3)	(0.2)	(0.4)	(0.5)	EPS (normalised)	(20.9)	(6.9)	(0.6)	(4.8)	(3.3)	(3.7)		
EBIT	(13.9)	(7.9)	(7.8)	(5.1)	1.3	EPS (reported)	(20.9)	(6.9)	(0.6)	(4.8)	(3.3)	(3.7)		
Interest	0.0	0.0	0.0	(0.0)	(0.1)	Dividend (cps)	0.0	0.0	0.0	0.0	0.0	0.0		
Tax	0.0	0.0	0.1	0.0	(0.5)	Imputation	30.0	30.0	30.0	30.0	30.0	30.0		
Minorities	0.0	0.0	0.0	0.0	0.0	Operating cash flow	(2.2)	(2.3)	(3.4)	(4.3)	(1.7)	(4.3)		
Equity accounted assoc	0.0	0.0	0.0	0.0	0.0	Free Cash flow	(0.8)	(1.0)	(2.0)	(3.2)	(0.1)	(1.8)		
NPAT pre significant items	(15.5)	(8.0)	(7.8)	(5.1)	0.7	Divisionals	H1CY18A	H2CY18A	H1CY19A	H2CY19A	H1CY20A	H2CY20F		
Significant items	0.0	0.0	0.0	0.0	0.0	Total Brain - Corporate	0.7	0.9	0.9	1.1	1.2	1.3		
NPAT (reported)	(15.5)	(8.0)	(7.8)	(5.1)	0.7	Total Brain Affinity	0.4	-	0.2	0.1	0.3	0.6		
Cash flow (A\$m)						Other revenues	0.5	0.2	0.4	1.0	0.2	0.2		
Y/E December 31	CY18A	CY19A	CY20F	CY21F	CY22F	Total Revenue	1.5	1.1	1.5	2.2	1.7	2.0		
EBITDA	(10.2)	(7.5)	(7.6)	(4.6)	1.8	Gross profit	1.5	1.0	1.3	1.8	1.4	1.9		
Interest	0.0	0.0	0.0	(0.0)	(0.1)	Gross Profit Margin %	331%	416%	339%	176%	753%	1134%		
Tax	0.0	0.0	0.0	0.0	(0.5)									
Working capital changes	5.7	(0.1)	1.5	2.6	(0.2)	Employment	2.3	2.8	2.7	3.7	3.1	4.0		
Operating cash flow	(4.5)	(7.7)	(6.0)	(2.0)	1.0	Marketing	0.2	0.4	0.4	0.4	0.5	0.4		
Mtce capex	0.0	(0.0)	(0.1)	(0.1)	(0.1)	Other costs	1.3	1.2	1.3	1.5	1.2	1.2		
Free cash flow	(4.5)	(7.7)	(6.1)	(2.1)	0.9	Total costs	3.7	4.4	4.4	5.6	4.8	5.6		
Growth capex	(2.8)	(2.5)	(4.0)	(2.0)	(2.0)									
Acquisitions/Disposals	0.0	0.0	0.0	0.0	0.0	EBITDA	(2.2)	(3.4)	(3.1)	(3.8)	(3.4)	(3.8)		
Other	(0.1)	0.1	0.0	0.0	0.0	EBITDA margin %	nm	nm	nm	nm	nm	nm		
Cash flow pre financing	(7.4)	(10.0)	(10.2)	(4.1)	(1.1)									
Equity	1.2	14.8	5.6	0.0	0.0	Margins, Leverage, Returns	CY18A	CY19A	CY20F	CY21F	CY22F			
Debt	0.0	0.0	1.1	0.0	0.0	EBITDA margin %	(384.5%)	(204.7%)	(204.8%)	-46%	9%			
Dividends paid	0.0	0.0	0.0	0.0	0.0	EBIT margin %	(521.2%)	(215.3%)	(212.6%)	-51%	7%			
Net cash flow for year	(6.1)	4.7	(3.5)	(4.1)	(1.1)	NPAT margin (pre significant items)	(582.8%)	(216.3%)	(211.1%)	-51%	4%			
Balance sheet (A\$m)						Net Debt (Cash)	3.27	7.62	2.72	-	1.35	-	2.47	
Y/E December 31	CY18A	CY19A	CY20F	CY21F	CY22F	Net debt/EBITDA (x)	(x)	n/a	n/a	n/a	n/a	-	1.38	
Cash	3.3	7.6	3.7	(0.4)	(1.5)	ND/ND+Equity (%)	(%)	(22.9%)	(46.2%)	(14.1%)	7.4%	12.3%		
Accounts receivable	0.5	2.5	2.5	1.0	1.4	EBIT interest cover (x)	(x)	n/a	n/a	n/a	n/a	8.3%		
Inventory	0.0	0.0	0.0	0.0	0.0	ROA		(62.3%)	(36.1%)	(31.6%)	(22.7%)	6.1%		
Other current assets	0.1	0.3	0.4	0.4	0.4	ROE		(94.3%)	(38.3%)	(33.8%)	(26.2%)	4.1%		
Total current assets	3.8	10.4	6.6	1.0	0.3	ROIC		(102.9%)	(223.5%)	(96.0%)	(84.2%)	14.6%		
PPE	0.2	0.2	0.3	0.4	0.4	NTA (per share)		33.0%	41.1%	23.2%	15.6%	16.2%		
Goodwill	0.0	0.0	0.0	0.0	0.0	Working capital		(6.6%)	193.3%	199.3%	75.3%	111.9%		
Investments	0.0	0.0	0.0	0.0	0.0	WC/Sales (%)		(2.5%)	52.4%	54.0%	7.6%	5.8%		
Deferred tax asset	0.0	0.0	0.0	0.0	0.0	Revenue growth		12.3%	38.5%	0.1%	167.4%	96.5%		
Other non current assets	14.5	14.7	17.4	18.9	20.5	EBIT growth pa		n/a	n/a	n/a	n/a	(125.1%)		
Total non current assets	14.8	15.0	17.7	19.3	20.9	Pricing	CY18A	CY19A	CY20F	CY21F	CY22F			
Total Assets	18.6	25.4	24.3	20.3	21.1	No of shares (y/e)	(m)	53	95	108	108	108		
Accounts payable	0.5	0.6	0.5	0.2	0.2	Weighted Av Dil Shares	(m)	590	95	108	108	108		
Short term debt	0.0	0.0	1.0	1.0	1.0									
Tax payable	0.0	0.0	0.0	0.0	0.0	EPS Reported	cps	(29.19)	(9.97)	(7.06)	(4.69)	0.65		
Deferred revenue	0.4	0.6	0.8	2.2	2.3	EPS Normalised/Diluted	cps	(29.19)	(9.97)	(7.06)	(4.69)	0.65		
Total current liabilities	0.9	1.1	2.3	3.4	3.6	EPS growth (norm/dil)		n/a	n/a	n/a	n/a	-114%		
Long term debt	0.0	0.0	0.0	0.0	0.0	DPS	cps	-	-	-	-	-		
Other non current liab	0.1	0.1	0.0	0.0	0.0	DPS Growth		n/a	n/a	n/a	n/a	n/a		
Total long term liabilities	0.1	0.1	0.0	0.0	0.0	Dividend yield		0.0%	0.0%	0.0%	0.0%	0.0%		
Total Liabilities	1.0	1.2	2.3	3.4	3.6	Dividend imputation		30	30	30	30	30		
Net Assets	17.5	24.1	21.9	16.9	17.6	PE (x)		-	-	-	-	47.4		
						PE market		18	18	18	18	18		
Share capital	58.1	72.6	78.4	78.4	78.4	Premium/(discount)			(100.0%)	(100.0%)	(100.0%)	163.2%		
Accumulated profits/losses	(44.8)	(52.7)	(60.5)	(65.6)	(64.8)	EV/EBITDA		(2.3)	(3.2)	(3.1)	-	7.1	20.3	
Reserves	4.2	4.3	4.0	4.0	4.0	FCF/Share	cps	(7.3)	(5.9)	(5.4)	-4.3	-1.6		
Minorities	0.0	0.0	0.0	0.0	0.0	Price/FCF share		(4.2)	(5.2)	(5.7)	-	7.1	19.2	
Total Shareholder funds	17.5	24.1	21.9	16.9	17.6	Free Cash flow Yield		(23.6%)	(19.1%)	(17.5%)	(14.0%)	(5.2%)		

Source: RaaS Advisory

FINANCIAL SERVICES GUIDE

RaaS Advisory Pty Ltd

ABN 99 614 783 363

Corporate Authorised Representative, number 1248415

of

BR SECURITIES AUSTRALIA PTY LTD

ABN 92 168 734 530

AFSL 456663

Effective Date: 26th November 2018

About Us

BR Securities Australia Pty Ltd (BR) is the holder of Australian Financial Services License ("AFSL") number 456663. RaaS Advisory Pty Ltd (RaaS) is an Authorised Representative (number 1248415) of BR.

This Financial Service Guide (FSG) is designed to assist you in deciding whether to use RaaS's services and includes such things as

- who we are
- our services
- how we transact with you
- how we are paid, and
- complaint processes

Contact Details, BR and RaaS

BR Head Office: Level 14, 344 Queen Street, Brisbane, QLD, 4000

RaaS. 20 Halls Road Arcadia, NSW 2159

P: +61 414 354712

E: finola.burke@raasgroup.com

RaaS is the entity providing the authorised AFSL services to you as a retail or wholesale client.

What Financial Services are we authorised to provide? RaaS is authorised to

- provide general advice to retail and wholesale clients in relation to
 - Securities
- deal on behalf of retail and wholesale clients in relation to
 - Securities

The distribution of this FSG by RaaS is authorized by BR.

Our general advice service

Please note that any advice given by RaaS is general advice, as the information or advice given will not take into account your particular objectives, financial situation or needs. You should, before acting on the advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Prospectus, Product Disclosure Statement or like instrument. As we only provide general advice we will not be providing a Statement of Advice. We will provide you with recommendations on securities

Our dealing service

RaaS can arrange for you to invest in securities issued under a prospectus by firstly sending you the offer document and then assisting you fill out the application form if needed.

How are we paid?

RaaS earns fees for producing research reports. Sometimes these fees are from companies for producing research reports and/or a financial model. When the fee is derived from a company, this is clearly highlighted on the front page of the report and in the disclaimers and disclosures section of the report.

We may also receive a fee for our dealing service, from the company issuing the securities.

Associations and Relationships

BR, RaaS, its directors and related parties have no associations or relationships with any product issuers other than when advising retail clients to invest in managed funds when the managers of these funds may also be clients of BR. RaaS's representatives may from time to time deal in or otherwise have a financial interest in financial products recommended to you but any material ownership will be disclosed to you when relevant advice is provided.

Complaints

If you have a complaint about our service you should contact your representative and tell them about your complaint. The representative will follow BR's internal dispute resolution policy, which includes sending you a copy of the policy when required to. If you aren't satisfied with an outcome, you may contact AFCA, see below. BR is a member of the Australian Financial Complaints Authority (AFCA). AFCA provide fair and independent financial services complaint resolution that is free to consumers.

Website: www.afca.org.au; Email: info@afca.org.au; Telephone: 1800931678 (free call)

In writing to: Australian Financial Complaints Authority, GPO Box 3, Melbourne, VIC, 3001.

Professional Indemnity Insurance

BR has in place Professional Indemnity Insurance which satisfies the requirements for compensation under s912B of the Corporations Act and that covers our authorized representatives.

DISCLAIMERS and DISCLOSURES

This report has been commissioned by Total Brain Ltd prepared and issued by RaaS Advisory Pty Ltd. RaaS Advisory has been paid a fee to prepare this report. RaaS Advisory's principals, employees and associates may hold shares in companies that are covered and, if so, this will be clearly stated on the front page of each report. This research is issued in Australia by RaaS Advisory and any access to it should be read in conjunction with the Financial Services Guide on the preceding two pages. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable. Opinions contained in this report represent those of the principals of RaaS Advisory at the time of publication. RaaS Advisory provides this financial advice as an honest and reasonable opinion held at a point in time about an investment's risk profile and merit and the information is provided by the RaaS Advisory in good faith. The views of the adviser(s) do not necessarily reflect the views of the AFS Licensee. RaaS Advisory has no obligation to update the opinion unless RaaS Advisory is currently contracted to provide such an updated opinion. RaaS Advisory does not warrant the accuracy of any information it sources from others. All statements as to future matters are not guaranteed to be accurate and any statements as to past performance do not represent future performance.

Assessment of risk can be subjective. Portfolios of equity investments need to be well diversified and the risk appropriate for the investor. Equity investments in listed or unlisted companies yet to achieve a profit or with an equity value less than \$50 million should collectively be a small component of a balanced portfolio, with smaller individual investment sizes than otherwise.

The science of climate change is common knowledge and its impacts may damage the global economy. Mitigating climate change may also disrupt the global economy. Investors need to make their own assessments and we disclaim any liability for the impact of either climate change or mitigating strategies on any investment we recommend.

Investors are responsible for their own investment decisions, unless a contract stipulates otherwise. RaaS Advisory does not stand behind the capital value or performance of any investment. Subject to any terms implied by law and which cannot be excluded, RaaS Advisory shall not be liable for any errors, omissions, defects or misrepresentations in the information (including by reasons of negligence, negligent misstatement or otherwise) or for any loss or damage (whether direct or indirect) suffered by persons who use or rely on the information. If any law prohibits the exclusion of such liability, RaaS Advisory limits its liability to the re-supply of the Information, provided that such limitation is permitted by law and is fair and reasonable. Copyright 2021 RaaS Advisory Pty Ltd (A.B.N. 99 614 783 363). All rights reserved.